Chronic myeloid leukaemia
Not recruitingStudy on Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: Comparing Dasatinib, Imatinib, Nilotinib, and Bosutinib Strategies
Study on Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: Comparing Dasatinib, Imatinib, Nilotinib, and Bosutinib Strategies
- Disease:Chronic myeloid leukaemia
- Substances:BosutinibDasatinib+2
France- Participants:18–64 years · 65+ years
- Substances:Bosutinib
- Sponsor:Centre Hospitalier Universitaire De Poitiers









